Menu
Search
|

Menu

Close
X

ACADIA Pharmaceuticals Inc ACAD.OQ (NASDAQ Stock Exchange Global Select Market)

16.33 USD
+0.38 (+2.38%)
As of Jun 22
chart
Previous Close 15.95
Open 16.01
Volume 6,700,813
3m Avg Volume 819,962
Today’s High 16.36
Today’s Low 15.78
52 Week High 41.20
52 Week Low 14.52
Shares Outstanding (mil) 122.40
Market Capitalization (mil) 4,717.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
49
FY17
125
FY16
17
FY15
0
EPS (USD)
FY18
-0.435
FY17
-1.807
FY16
-2.335
FY15
-1.634
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
74.89
5.71
Price to Book (MRQ)
vs sector
11.36
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
0.00
16.46
LT Debt to Equity (MRQ)
vs sector
0.00
12.19
Return on Investment (TTM)
vs sector
-74.14
14.38
Return on Equity (TTM)
vs sector
-74.18
16.08

EXECUTIVE LEADERSHIP

Stephen Biggar
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Stephen Davis
President, Chief Executive Officer, Director, Since 2016
Salary: $675,992.00
Bonus: $437,705.00
Todd Young
Executive Vice President, Chief Financial Officer, Since 2016
Salary: $147,462.00
Bonus: $61,381.00
Glenn Baity
Executive Vice President, General Counsel, Secretary, Since 2014
Salary: $407,000.00
Bonus: $169,414.00
Srdjan Stankovic
Executive Vice President, Head - Research and Development, Since 2015
Salary: $475,000.00
Bonus: $219,688.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3611 Valley Centre Dr Ste 300
SAN DIEGO   CA   92130-3331

Phone: +1858.5582871

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

SPONSORED STORIES